- Joined
- Oct 4, 2017
- Messages
- 5,290
- Reaction score
- 10,354
"It might portend a further softening of the radiation oncology job market as physicians are hired less frequently than they are now."
So you aren't opposed to ROCR because of ROCR, you are opposed to ROCR because ASTRO proposed it... got it.
I'm getting heated. I'll step away for a while
This is wrong. I did not see the webinar, but it is interesting that they tried to address consolidation (perhaps due to concerns mentioned here).But it does impact non-employed docs. So if we leave the system as is, employed docs are fine, hospitals get more technical rates, and it further accelerates the already-existing trend to consolidation.
But it does impact non-employed docs. So if we leave the system as is, employed docs are fine, hospitals get more technical rates, and it further accelerates the already-existing trend to consolidation.
It's an interesting bait-and-switch here at SDN where we complained for so long that ASTRO only had academics and ignored PP. They make a proposal to help PP/freestanding and now we're all employed docs who aren't helped by their proposals. 🙄
Come on, you know that's not true. At least not from me.So you aren't opposed to ROCR because of ROCR, you are opposed to ROCR because ASTRO proposed it... got it.
I'm getting heated. I'll step away for a while
exactly. Even if technical component is not cut (or somehow increases slightly) , we still have the same problemNot against case rates in principal, but if 77427 OTV requirement disappears and hospital OPD only requires general supervision, why would the hospitals, whose technical component reimbursement has been cut by ROCR not simply contract a .25 FTE radonc to see consults and sign plans (and subsequently disappear), thereby almost instantly reducing the need for much of our specialty? I'm not one for "sky is falling" scenarios but I see this as the immediate danger if ROCR is implemented.
It was mentioned in the webinar that for medicare crossovers, one would still have to bill out the CPTs so its not clear to me what is intended. It's almost like they think nothing will change in hospital/corporate/physician behavior if ROCR is implemented
Not against case rates in principal, but if 77427 OTV requirement disappears and hospital OPD only requires general supervision, why would the hospitals, whose technical component reimbursement has been cut by ROCR not simply contract a .25 FTE radonc to see consults and sign plans (and subsequently disappear), thereby almost instantly reducing the need for much of our specialty? I'm not one for "sky is falling" scenarios but I see this as the immediate danger if ROCR is implemented.
It was mentioned in the webinar that for medicare crossovers, one would still have to bill out the CPTs so its not clear to me what is intended. It's almost like they think nothing will change in hospital/corporate/physician behavior if ROCR is implemented
I think thats a good idea. Nobody except those that a) don't understand it or b) aren't affected by it wants ROCR.So you aren't opposed to ROCR because of ROCR, you are opposed to ROCR because ASTRO proposed it... got it.
I'm getting heated. I'll step away for a while
Not against case rates in principal, but if 77427 OTV requirement disappears and hospital OPD only requires general supervision, why would the hospitals, whose technical component reimbursement has been cut by ROCR not simply contract a .25 FTE radonc to see consults and sign plans (and subsequently disappear), thereby almost instantly reducing the need for much of our specialty? I'm not one for "sky is falling" scenarios but I see this as the immediate danger if ROCR is implemented.
It was mentioned in the webinar that for medicare crossovers, one would still have to bill out the CPTs so its not clear to me what is intended. It's almost like they think nothing will change in hospital/corporate/physician behavior if ROCR is implemented
And as long as there is a huge supply of "new" labor, hospitals must be salivating at the prospect of ROCR. Meanwhile, those with "Secure" academic jobs or sitting in exempt centers or proton sites are just laughing..
![]()
Depends on what you mean by "secure." Even if you're an associate professor (or higher), these forces will work to decrease your mobility and stagnate salaries in the face of inflation.And as long as there is a huge supply of "new" labor, hospitals must be salivating at the prospect of ROCR. Meanwhile, those with "Secure" academic jobs or sitting in exempt centers or proton sites are just laughing..
![]()
Dr Milligan, ASTRO, ROCR cmte, et al:Well the question is, which version of the story do we want to believe?
In late 2021, the Red Journal had an issue on consolidation as @NotMattSpraker mentioned.
They did a podcast on it, with Zietman interviewing Miranda Lam and the new grad from the ROCR Town Hall, Milligan.
View attachment 374749
Go listen for yourself. Here are key excerpts with the opinion expressed on that podcast, and the opinion expressed on the Town Hall:
AZ:
One sort of economic threat on the horizon is the new alternative payment model, which is going to bundle payments and radiation oncologists specifically will take quite a hit from this. Do you think that is going to drive more groups into consolidation?
Lam:
My sense is that if we were to look at the data, that there may be an uptick in terms of consolidation. I do think that there is concern.
About practices that may not be able to feel comfortable financially to stay open and look for other practices to merge with other hospitals to work with, or, private equity firms to buy them. And so I do think that there is a real chance that consolidation may increase. I think another interesting component that Dr. Milligan and I have talked about is that the impact that the bundled payments in radiation oncology might have on vulnerable populations. So if we think about some of these practices that have one or two radiation oncologists, if they are randomized into the bundled payment model, they may feel more financial pressures.
and either have to close down or find ways to keep the practice open with less resources. And I think in those cases, we're really hurting some of these populations that may already have difficulty accessing care in our rural areas, in areas that care for, more minorities. And so I think it is definitely of concern on many levels, not just for, potential consolidation and increase in prices.
But, I think just the actual threat of what are going to happen to practices. Are we going to see practices, just the sheer number of radiation practices decrease overall?
AZ:
Is there anything that you can imagine that might change this trend to consolidation? Where is it all going to end?
Milligan:
That's an excellent question. In terms of factors that might slow down or reverse consolidation, it's... It's frankly hard to imagine what those might be.
But perhaps it's just my own lack of imagination that it's a little hard for me to come up with any particular factors that might reverse this trend we've seen. One in 11 dermatologists in the United States practiced in a PE or private equity owned firm. These practices were more likely to hire a larger share of advanced Practice providers like NPs or PAs and really drove much higher patient volumes in private equity owned firms compared to those firms that were not owned by private equity companies.
So patient volumes were five to 17% higher. The use of expensive interventions were, was also significantly higher. And, if we were to see similar trends in radiation oncology might portend a future where radiation oncologists are employed by only a few large firms with owners being hospitals, private equity companies, things like that.
It might portend a further softening of the radiation oncology job market as physicians are hired less frequently than they are now.
AZ:
Boy, that's a real doomsday scenario. I think private equity companies are getting involved in some practices in radiation oncology, though I think they've only just begun.
ROCR Town Hall -
Anne:
This next one is for Dr. Milligan. How would the shift to ROCR impact the trend towards consolidation of practices?
Milligan:
Radiation oncology is consolidating quick. It's one of the most consolidated specialties in the United States. And I think that ROCR will address some of those issues that will certainly make our finances more stable going forward, which can help in the prediction.
And, not having wide confidence intervals in our sensitivity analyses can sort of help not only provide more clarity about where we're going, but also allow you to use your capital a little more wisely. To summarize, ROCR, stabilizes or, at least stabilizes our payments and may address some of the increasing costs as well. So I think it will have it's hard to predict, but I think it will have a positive effect in sort of reducing the rates of consolidation going forward.
The reason consolidation is being talked about as a "benefit" of ROCR here is because it's not a benefit.
What did the 5 fingers say to the face?Dr Milligan, ASTRO, ROCR cmte, et al:
![]()
You sound like an ASTRO shill with these posts honestly. It needs to be a fair and equally applied system and ignores the workforce elephant in the roomBut it does impact non-employed docs. So if we leave the system as is, employed docs are fine, hospitals get more technical rates, and it further accelerates the already-existing trend to consolidation.
It's an interesting bait-and-switch here at SDN where we complained for so long that ASTRO only had academics and ignored PP. They make a proposal to help PP/freestanding and now we're all employed docs who aren't helped by their proposals. 🙄
Not helping yourself here. Just look at Astro's history. They were on the wrong side of payment bundles and urorads over a decade ago. They are being reactive now just like they were with APM. Their attitude towards protons lately vs the imrt/fraction/urorads/pp shaming for years speaks volumes to their priorities and their interests.So you aren't opposed to ROCR because of ROCR, you are opposed to ROCR because ASTRO proposed it... got it.
I'm getting heated. I'll step away for a while
Uh...as far as I can tell, there's the 6 distinct individuals from the original webinar and the Town Hall, then Sameer, and...I would say between Twitter and SDN, maybe 3-4 more "soft" supporters, recognizing that there might be some overlap because of the "anonymous" nature of SDN.Poor ROCR and all its shills.
Uh...as far as I can tell, there's the 6 distinct individuals from the original webinar and the Town Hall, then Sameer, and...I would say between Twitter and SDN, maybe 3-4 more "soft" supporters, recognizing that there might be some overlap because of the "anonymous" nature of SDN.
Literally, literally there seems to be <12 people supporting this at ASTRO, and two of those are non-physicians.
Which is...sort of my main point. For the same reason I don't think ASTRO as an entity is all bad, I also don't think "ASTRO" as an abstract entity can "support" anything.
It's the people within ASTRO that I'm curious about. Who are you, you mysterious authors? How many?
In total:Consider that the president of ASTRO has never tweeted, messaged, or appeared on anything related to ROCR.
Wasn't one of the major reasons that the APM was "pro-consolidation" was that there were draconian documentation/EMR requirements that would have required small centers to shell out huge sums of money to meet requirements? (whereas large centers already had the infrastructure to accommodate the requirements). My (albeit limited) understanding of the ROCR is that it wouldn't have these same requirements.Well the question is, which version of the story do we want to believe?
In late 2021, the Red Journal had an issue on consolidation as @NotMattSpraker mentioned.
They did a podcast on it, with Zietman interviewing Miranda Lam and the new grad from the ROCR Town Hall, Milligan.
View attachment 374749
Go listen for yourself. Here are key excerpts with the opinion expressed on that podcast, and the opinion expressed on the Town Hall:
AZ:
One sort of economic threat on the horizon is the new alternative payment model, which is going to bundle payments and radiation oncologists specifically will take quite a hit from this. Do you think that is going to drive more groups into consolidation?
Lam:
My sense is that if we were to look at the data, that there may be an uptick in terms of consolidation. I do think that there is concern.
About practices that may not be able to feel comfortable financially to stay open and look for other practices to merge with other hospitals to work with, or, private equity firms to buy them. And so I do think that there is a real chance that consolidation may increase. I think another interesting component that Dr. Milligan and I have talked about is that the impact that the bundled payments in radiation oncology might have on vulnerable populations. So if we think about some of these practices that have one or two radiation oncologists, if they are randomized into the bundled payment model, they may feel more financial pressures.
and either have to close down or find ways to keep the practice open with less resources. And I think in those cases, we're really hurting some of these populations that may already have difficulty accessing care in our rural areas, in areas that care for, more minorities. And so I think it is definitely of concern on many levels, not just for, potential consolidation and increase in prices.
But, I think just the actual threat of what are going to happen to practices. Are we going to see practices, just the sheer number of radiation practices decrease overall?
AZ:
Is there anything that you can imagine that might change this trend to consolidation? Where is it all going to end?
Milligan:
That's an excellent question. In terms of factors that might slow down or reverse consolidation, it's... It's frankly hard to imagine what those might be.
But perhaps it's just my own lack of imagination that it's a little hard for me to come up with any particular factors that might reverse this trend we've seen. One in 11 dermatologists in the United States practiced in a PE or private equity owned firm. These practices were more likely to hire a larger share of advanced Practice providers like NPs or PAs and really drove much higher patient volumes in private equity owned firms compared to those firms that were not owned by private equity companies.
So patient volumes were five to 17% higher. The use of expensive interventions were, was also significantly higher. And, if we were to see similar trends in radiation oncology might portend a future where radiation oncologists are employed by only a few large firms with owners being hospitals, private equity companies, things like that.
It might portend a further softening of the radiation oncology job market as physicians are hired less frequently than they are now.
AZ:
Boy, that's a real doomsday scenario. I think private equity companies are getting involved in some practices in radiation oncology, though I think they've only just begun.
ROCR Town Hall -
Anne:
This next one is for Dr. Milligan. How would the shift to ROCR impact the trend towards consolidation of practices?
Milligan:
Radiation oncology is consolidating quick. It's one of the most consolidated specialties in the United States. And I think that ROCR will address some of those issues that will certainly make our finances more stable going forward, which can help in the prediction.
And, not having wide confidence intervals in our sensitivity analyses can sort of help not only provide more clarity about where we're going, but also allow you to use your capital a little more wisely. To summarize, ROCR, stabilizes or, at least stabilizes our payments and may address some of the increasing costs as well. So I think it will have it's hard to predict, but I think it will have a positive effect in sort of reducing the rates of consolidation going forward.
The reason consolidation is being talked about as a "benefit" of ROCR here is because it's not a benefit.
Wasn't one of the major reasons that the APM was "pro-consolidation" was that there were draconian documentation/EMR requirements that would have required small centers to shell out huge sums of money to meet requirements? (whereas large centers already had the infrastructure to accommodate the requirements). My (albeit limited) understanding of the ROCR is that it wouldn't have these same requirements.
I think that @grenz raises a good point. It is unrealistic to expect any one intervention to solve the many problems faced by our field.
We should all start off by asking the right question: On average, would we be better off implementing the ROCR or allowing the current system to stay in place. It's not a question of whether ROCR will ELIMINATE the pain... but whether it will IMPROVE the pain. So would ROCR help or hurt? (personally, I haven't made up my mind yet)
It's going to hurt in the long run without question.This is a fair/good post.
And it is REALLY hard to figure that out, and it will vary from practice to practice. So many considerations.
I think one heuristic about all of it is that if/when it's hard to figure it out, then you fall back on "gut feeling" and "trust" and "transparency." And that's where the challenges are for ASTRO. A lot of that trust is lost with past ASTRO misdeeds, proton exemptions and things like "registry trial" support in choosing wisely, blind eyes to PPS exemptions, people exempt from rules writing rules, etc.
Your post is a reminder though that at the end of the day the ROCR help/hurt, is the real question.
Wasn't one of the major reasons that the APM was "pro-consolidation" was that there were draconian documentation/EMR requirements that would have required small centers to shell out huge sums of money to meet requirements? (whereas large centers already had the infrastructure to accommodate the requirements). My (albeit limited) understanding of the ROCR is that it wouldn't have these same requirements.
I think one heuristic about all of it is that if/when it's hard to figure it out, then you fall back on "gut feeling" and "trust" and "transparency."
I would have to go back and listen to the Town Hall again to answer your point/question thoroughly. That was one of the concerns about APM, yes. I don't believe ROCR has the same level of documentation requirements, but it's not going to have less documentation requirements (that part I remember)...and documentation alone won't make or break a practice surviving. But it's definitely worth pointing out.Wasn't one of the major reasons that the APM was "pro-consolidation" was that there were draconian documentation/EMR requirements that would have required small centers to shell out huge sums of money to meet requirements? (whereas large centers already had the infrastructure to accommodate the requirements). My (albeit limited) understanding of the ROCR is that it wouldn't have these same requirements.
I think that @grenz raises a good point. It is unrealistic to expect any one intervention to solve the many problems faced by our field.
We should all start off by asking the right question: On average, would we be better off implementing the ROCR or allowing the current system to stay in place. It's not a question of whether ROCR will ELIMINATE the pain... but whether it will IMPROVE the pain. So would ROCR help or hurt? (personally, I haven't made up my mind yet)
(Disclaimer: The following essay is written in the style of Eminem, focusing on strong and passionate language.)
Title: "Medical Care's Dark Melody: The Pitfalls of Bundled Payment Models"
Verse 1:
Yo, let me spit some truth, no games to play,
Bundled payment models, they lead us astray,
In the medical realm, it's all about the pay,
But these setups got us facing a darker day.
Chorus:
Bundled payments, they seem fine, at first sight,
But dig deeper, you'll see the hidden fight,
They're horrible, causing struggles day and night,
It's time to shed some light, to make things right.
Verse 2:
They say it's efficient, costs will go down,
But in reality, some patients will drown,
Providers rush, cutting corners all around,
Quality compromised, and care can't be found.
Chorus:
Bundled payments, they seem fine, at first sight,
But dig deeper, you'll see the hidden fight,
They're horrible, causing struggles day and night,
It's time to shed some light, to make things right.
Verse 3:
Complex cases, left in the dust,
Underpaid treatments, they start to rust,
Equality suffers, some get left unjust,
In this medical system, who can you trust?
Chorus:
Bundled payments, they seem fine, at first sight,
But dig deeper, you'll see the hidden fight,
They're horrible, causing struggles day and night,
It's time to shed some light, to make things right.
Verse 4:
The heart of medicine, it's empathy and care,
But bundled payments got us walking on thin air,
Profits dictate, leaving some in despair,
The essence of healing, they're starting to tear.
Chorus:
Bundled payments, they seem fine, at first sight,
But dig deeper, you'll see the hidden fight,
They're horrible, causing struggles day and night,
It's time to shed some light, to make things right.
Outro:
In conclusion, we gotta rethink this game,
Bundled payment models, they're not the same,
Let's find a balance, and break free from the shame,
Revive compassion, restore medicine's flame.
I need a real rapper to do this song. Then post someone to post it on ROhub.GPT working hard
I’ve never seen 340. I’m working for one now for $125. Evicore was $115 6 years ago.When you're really truly ready to give up.. just know..
Your favorite UM company is hiring Rad Onc Directors. Used to be ~ 340k/4d work week (10 hrs/d) plus 5 weeks vacation years ago. And a year end bonus of maybe 10%. You know, when Radonc was still good. Not fun, but for those trapped, doable.
Wanna take a gander at what it is now?
Hows 250k and 2 week vacation sound.. hits ya right in the feelz don't it? And you will have every last ounce of productivity squeezed out of you.
On your knees, serf.
![]()
Oh, and full time get “unlimited time off” whatever that’s supposed to mean, as long as all cases get reviewed.I’ve never seen 340. I’m working for one now for $125. Evicore was $115 6 years ago.
Full time effort paying 125k a year?I’ve never seen 340. I’m working for one now for $125. Evicore was $115 6 years ago.
CMS already looking to extend tele into 2024.... I think many of us feel that genie isn't going back into the bottleStill no word on supervision req changes with ROCR and code obliteration
Yeah, I suspect you'll be hard pressed to find anyone giving a real answer there.Still no word on supervision req changes with ROCR and code obliteration
Rad onc billers/coders have had to put their goalposts on wheels these past few yearsYeah, I suspect you'll be hard pressed to find anyone giving a real answer there.
Rather than have any level of creativity, all efforts, as weak as they are, focus on maintaining the classic way clinical RadOnc gets reimbursement.
A big part of that for many years now has been linac babysitting.
When CMS announced the general supervision change in November 2019, it sent the establishment into panic. The multi-step argument construction they wrote as a white paper, pretzel-logic building IGRT as a diagnostic test, is...well, it's special. It hasn't been supported in any case law, we'll put it like that.
Then when the pandemic ushered in the tele-supervision rules, which are now in effect until the end of 2024, it became moot. I agree with @medgator - those are likely here to stay.
However, it appears the establishment knows it's out of fake arguments. I was recently in a billing seminar with one of the major RadOnc agencies and none of this was mentioned at all. Supervision was entirely glossed over until an audience member asked, then there was a lot of dodging, and finally they invoked site of service requirements for professional billing.
It was...magnificent.
Cbct is diagnostic, despite the fda/varian explicitly stating that it is not diagnostic. Beyond abdsurd.Rad onc billers/coders have had to put their goalposts on wheels these past few years
I've never seen a single diagnostic report generated from a CBCT sent to a referring physician. EverCbct is diagnostic, despite the fda/varian explicitly stating that it is not diagnostic. Beyond abdsurd.